 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 5 | 1/1 | 返回列表 |
| 查看: 1184 | 回復(fù): 4 | |||||||
1949stone榮譽(yù)版主 (知名作家)
海納百川
|
[交流]
New Drugs at FDA 已有4人參與
|
|
http://www.fda.gov/Drugs/Develop ... ovation/default.htm New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products 2014 Novel New Drugs Summary 2014 Novel New Drugs Summary (PDF - 13MB) Innovation drives progress. When it comes to innovation in the development of new drugs and therapeutic biological products, FDA’s Center for Drug Evaluation and Research (CDER) supports the pharmaceutical industry at every step of the process. With its understanding of the science used to create new products, testing and manufacturing procedures, and the diseases and conditions that new products are designed to treat, FDA provides scientific and regulatory advice needed to bring new therapies to market. The availability of new drugs and biological products often means new treatment options for patients and advances in health care for the American public. For this reason, CDER supports innovation and plays a key role in helping to advance new drug development. Each year, CDER approves a wide range of new drugs and biological products. Some of these products are innovative new products that never before have been used in clinical practice. Others are the same as, or related to, previously approved products, and they will compete with those products in the marketplace. Certain drugs are classified as new molecular entities (“NMEs”) for purposes of FDA review. Many of these products contain active moieties that have not been approved by FDA previously, either as a single ingredient drug or as part of a combination product; these products frequently provide important new therapies for patients. Some drugs are characterized as NMEs for administrative purposes, but nonetheless contain active moieties that are closely related to active moieties in products that have previously been approved by FDA. For example, CDER classifies biological products submitted in an application under section 351(a) of the Public Health Service Act as NMEs for purposes of FDA review, regardless of whether the Agency previously has approved a related active moiety in a different product. FDA’s classification of a drug as an “NME” for review purposes is distinct from FDA’s determination of whether a drug product is a “new chemical entity” or “NCE” within the meaning of the Federal Food, Drug, and Cosmetic Act. Graph symbol View animated charts from the 2014 Novel New Drugs Summary publication on the right. (Not viewable in Internet Explorer version 7 and below.) |
回復(fù)此樓» 本帖附件資源列表
-
歡迎監(jiān)督和反饋：小木蟲僅提供交流平臺(tái)，不對(duì)該內(nèi)容負(fù)責(zé)。
本內(nèi)容由用戶自主發(fā)布，如果其內(nèi)容涉及到知識(shí)產(chǎn)權(quán)問(wèn)題，其責(zé)任在于用戶本人，如對(duì)版權(quán)有異議，請(qǐng)聯(lián)系郵箱：xiaomuchong@tal.com - 附件 1 : Novel_New_Drugs_2014_Summary.pdf
2015-01-16 10:27:25, 8.55 M
» 收錄本帖的淘帖專輯推薦
 顓頊藥學(xué) | 藥物研發(fā)知識(shí) | 搜藏-精-實(shí) | 研發(fā)專用 |
» 猜你喜歡
腦梗怎么治療
已經(jīng)有3人回復(fù)
-
腦梗怎么治療
已經(jīng)有0人回復(fù)
-
藥理學(xué)論文潤(rùn)色/翻譯怎么收費(fèi)?
已經(jīng)有223人回復(fù)
-
生物組織中有目標(biāo)分析物，專屬性怎么做
已經(jīng)有0人回復(fù)
» 本主題相關(guān)價(jià)值貼推薦，對(duì)您同樣有幫助:
- 大家對(duì)諾華諾德的 Semaglutide 前景怎么看？
已經(jīng)有11人回復(fù)
- FDA中提到的NMEs（New Molecular Entity 新分子實(shí)體）包括生物制品嗎？
已經(jīng)有4人回復(fù)
- 求助布地奈德的用途的文獻(xiàn)，妹子不勝感激
已經(jīng)有4人回復(fù)
- FDA批準(zhǔn)新藥Hemangeol上市
已經(jīng)有7人回復(fù)
- 怎樣能查到FDA剛批準(zhǔn)上市新藥的信息？
已經(jīng)有7人回復(fù)
- FDA延遲批準(zhǔn)葛蘭素史克GLP-1藥物阿必魯肽
已經(jīng)有7人回復(fù)
- 正大天晴3000萬(wàn)美元買入一個(gè)臨床前抗HCV藥物在中國(guó)地區(qū)的許可，天價(jià)?
已經(jīng)有15人回復(fù)
- Purdue Pharma：如何讓一個(gè)藥獨(dú)占市場(chǎng)30年？
已經(jīng)有9人回復(fù)
- FDA批準(zhǔn)強(qiáng)生Canagliflozin用于2型糖尿病
已經(jīng)有8人回復(fù)
- 關(guān)于New dosage form 和New formulation or new manufacturer 的翻譯問(wèn)題
已經(jīng)有5人回復(fù)
- 如何查上市藥物的藥理毒理資料？
已經(jīng)有8人回復(fù)
- 2011 FDA drug approvals
已經(jīng)有57人回復(fù)
- 阿尼芬凈的專利求助
已經(jīng)有12人回復(fù)
- 3類化藥藥效學(xué)試驗(yàn)劑量組的設(shè)置
已經(jīng)有22人回復(fù)
- 轉(zhuǎn)：具有全新降低血糖機(jī)制的新藥被fda專家小組否定
已經(jīng)有3人回復(fù)
- 【轉(zhuǎn)帖】藥品查詢網(wǎng)的數(shù)據(jù)庫(kù)
已經(jīng)有77人回復(fù)
- 【轉(zhuǎn)帖】杜克之問(wèn)：藥物試驗(yàn)全球化，到底誰(shuí)受益？
已經(jīng)有16人回復(fù)
- 【轉(zhuǎn)帖】國(guó)產(chǎn)PVP遭遇FDA發(fā)難，過(guò)氧化物超標(biāo)
已經(jīng)有7人回復(fù)
謝謝分享 |
2樓2015-01-16 10:37:55
|
謝謝分享 [ 發(fā)自小木蟲客戶端 ] |
3樓2015-01-17 06:56:20
臭笨笨
木蟲 (正式寫手)
- 應(yīng)助: 82 (初中生)
- 金幣: 1771.3
- 散金: 219
- 紅花: 3
- 帖子: 834
- 在線: 205.2小時(shí)
- 蟲號(hào): 3064652
- 注冊(cè): 2014-03-17
- 性別: GG
- 專業(yè): 藥劑學(xué)
4樓2015-01-17 15:51:29
| 感謝分享 |
5樓2015-01-19 08:39:02
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 1949stone 的主題更新
| 5 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 梁成偉老師課題組歡迎你的加入 +9 | 一鴨鴨喲 2026-03-14 | 11/550 |
|
|---|---|---|---|---|
|
|
[考研] 一志愿北京化工大學(xué)0703化學(xué)318分，有科研經(jīng)歷，求調(diào)劑 +3 | 一瓶苯甲酸 2026-03-14 | 3/150 |
|
|
[考研] 一志愿西安交通大學(xué)材料工程專業(yè) 282分求調(diào)劑 +5 | 楓橋ZL 2026-03-18 | 7/350 |
|
|
|
[考研] 286求調(diào)劑 +6 | lemonzzn 2026-03-16 | 10/500 |
|
|
|
[考研] 287求調(diào)劑 +3 | 晨昏線與星海 2026-03-19 | 4/200 |
|
|
|
[考研] 328求調(diào)劑，英語(yǔ)六級(jí)551，有科研經(jīng)歷 +4 | 生物工程調(diào)劑 2026-03-16 | 12/600 |
|
|
|
[考研] 311求調(diào)劑 +4 | 冬十三 2026-03-18 | 4/200 |
|
|
|
[考研] 354求調(diào)劑 +4 | Tyoumou 2026-03-18 | 7/350 |
|
|
|
[考研] 295求調(diào)劑 +3 | 一志愿京區(qū)211 2026-03-18 | 5/250 |
|
|
|
[考研] 297求調(diào)劑 +8 | 戲精丹丹丹 2026-03-17 | 8/400 |
|
|
|
[考研] 303求調(diào)劑 +4 | 睿08 2026-03-17 | 6/300 |
|
|
|
[考研] 0703化學(xué)調(diào)劑 +3 | 妮妮ninicgb 2026-03-17 | 3/150 |
|
|
|
[考研] 296求調(diào)劑 +5 | 大口吃飯 身體健 2026-03-13 | 5/250 |
|
|
|
[考研] 326求調(diào)劑 +5 | 上岸的小葡 2026-03-15 | 6/300 |
|
|
|
[考研] 材料工程專碩274一志愿211求調(diào)劑 +6 | 薛云鵬 2026-03-15 | 6/300 |
|
|
|
[考研] 333求調(diào)劑 +3 | 文思客 2026-03-16 | 7/350 |
|
|
|
[基金申請(qǐng)]
今年的國(guó)基金是打分制嗎？
 50+3
|
zhanghaozhu 2026-03-14 | 3/150 |
|
|
|
[考研] 0703化學(xué)調(diào)劑 290分有科研經(jīng)歷，論文在投 +7 | 膩膩gk 2026-03-14 | 7/350 |
|
|
|
[考研] 26考研一志愿中國(guó)石油大學(xué)(華東)305分求調(diào)劑 +3 | 嘉年新程 2026-03-15 | 3/150 |
|
|
|
[考研] 297求調(diào)劑 +4 | 學(xué)海漂泊 2026-03-13 | 4/200 |
|